Tapewire

Nasdaq · USD

RNA

Atrium Therapeutics, Inc.

Export transactions ↓
Tapewire entity
6185
SEC CIK
0002093101
Parsed reports
30

Last 12 months

Inside the activity.

0 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 18, 2026 Filed Sep 22, 2026 20:24 UTC
Younis HusamChief Scientific Officer
Tax withholdingCommon Stock 11,216 $8.95 $100,383.20
Disclosure

SEC source: 0001193125-26-397971 · ownership.xml · nonDerivative · entry 1

Younis Husam · CIK 0002107586 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,441

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 18, 2026 Filed Sep 22, 2026 20:23 UTC
Hughes Steven GeorgeChief Medical Officer
Tax withholdingCommon Stock 21,459 $8.95 $192,058.05
Disclosure

SEC source: 0001193125-26-397967 · ownership.xml · nonDerivative · entry 1

Hughes Steven George · CIK 0001747528 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,638

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 18, 2026 Filed Sep 22, 2026 20:20 UTC Tax withholdingCommon Stock 22,812 $8.95 $204,167.40
Disclosure

SEC source: 0001193125-26-397955 · ownership.xml · nonDerivative · entry 1

Flanagan W. Michael · CIK 0001841990 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,974

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 18, 2026 Filed Sep 22, 2026 20:20 UTC
Boyce SarahDirector
Tax withholdingCommon Stock 126,418 $8.95 $1,131,441.10
Disclosure

SEC source: 0001193125-26-397951 · ownership.xml · nonDerivative · entry 1

Boyce Sarah · CIK 0001629383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,668

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 18, 2026 Filed Sep 22, 2026 20:18 UTC
Kenney StephanieSee Remarks
Tax withholdingCommon Stock 2,375 $8.95 $21,256.25
Disclosure

SEC source: 0001193125-26-397948 · ownership.xml · nonDerivative · entry 1

Kenney Stephanie · CIK 0002105422 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,085

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 18, 2026 Filed Sep 22, 2026 20:17 UTC
Gallagher Kathleen P.Director · See Remarks
Tax withholdingCommon Stock 11,632 $8.95 $104,106.40
Disclosure

SEC source: 0001193125-26-397944 · ownership.xml · nonDerivative · entry 1

Gallagher Kathleen P. · CIK 0002048409 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,729

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 18, 2026 Filed Sep 22, 2026 20:17 UTC
Winslow Brendan R.Chief Financial Officer
Tax withholdingCommon Stock 6,742 $8.95 $60,340.90
Disclosure

SEC source: 0001193125-26-397941 · ownership.xml · nonDerivative · entry 1

Winslow Brendan R. · CIK 0002105552 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,859

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 18, 2026 Filed Sep 22, 2026 20:15 UTC
Hoyos Rocio MartinChief Strategy Officer
Tax withholdingCommon Stock 8,320 $8.95 $74,464.00
Disclosure

SEC source: 0001193125-26-397936 · ownership.xml · nonDerivative · entry 1

Hoyos Rocio Martin · CIK 0002107515 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,340

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 17:54 UTC
Hughes Steven GeorgeChief Medical Officer
GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $14.30 $0.00
Disclosure

SEC source: 0001193125-26-170963 · ownership.xml · derivative · entry 2

Hughes Steven George · CIK 0001747528 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-04-20

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 17:54 UTC
Hughes Steven GeorgeChief Medical Officer
GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-170963 · ownership.xml · nonDerivative · entry 1

Hughes Steven George · CIK 0001747528 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,097

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 17:43 UTC
Gallagher Kathleen P.Director · See Remarks
GrantStock Option (Right to Buy) · Derivative 205,000 $0.00 Strike: $14.30 $0.00
Disclosure

SEC source: 0001193125-26-170914 · ownership.xml · derivative · entry 2

Gallagher Kathleen P. · CIK 0002048409 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock · 205,000 shares

Expires 2036-04-20

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 17:43 UTC
Gallagher Kathleen P.Director · See Remarks
GrantCommon Stock 102,500 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-170914 · ownership.xml · nonDerivative · entry 1

Gallagher Kathleen P. · CIK 0002048409 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,361

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:54 UTC
Kenney StephanieSee Remarks
GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $14.30 $0.00
Disclosure

SEC source: 0001193125-26-170964 · ownership.xml · derivative · entry 2

Kenney Stephanie · CIK 0002105422 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-04-20

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:54 UTC
Kenney StephanieSee Remarks
GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-170964 · ownership.xml · nonDerivative · entry 1

Kenney Stephanie · CIK 0002105422 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,460

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:53 UTC
Winslow Brendan R.Chief Financial Officer
GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $14.30 $0.00
Disclosure

SEC source: 0001193125-26-170960 · ownership.xml · derivative · entry 2

Winslow Brendan R. · CIK 0002105552 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-04-20

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:53 UTC
Winslow Brendan R.Chief Financial Officer
GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-170960 · ownership.xml · nonDerivative · entry 1

Winslow Brendan R. · CIK 0002105552 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,601

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:41 UTC
Hoyos Rocio MartinChief Strategy Officer
GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $14.30 $0.00
Disclosure

SEC source: 0001193125-26-170907 · ownership.xml · derivative · entry 2

Hoyos Rocio Martin · CIK 0002107515 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-04-20

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:41 UTC
Hoyos Rocio MartinChief Strategy Officer
GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-170907 · ownership.xml · nonDerivative · entry 1

Hoyos Rocio Martin · CIK 0002107515 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,660

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:40 UTC
Younis HusamChief Scientific Officer
GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $14.30 $0.00
Disclosure

SEC source: 0001193125-26-170906 · ownership.xml · derivative · entry 2

Younis Husam · CIK 0002107586 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-04-20

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 20, 2026 Filed Apr 22, 2026 21:40 UTC
Younis HusamChief Scientific Officer
GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-170906 · ownership.xml · nonDerivative · entry 1

Younis Husam · CIK 0002107586 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,657

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
February 27, 2026 Filed Mar 2, 2026 23:00 UTC GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $14.75 $0.00
Disclosure

SEC source: 0001193125-26-085918 · ownership.xml · derivative · entry 1

Skerjanec Simona · CIK 0002022163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-02-27

F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
February 27, 2026 Filed Mar 2, 2026 23:00 UTC
Boyce SarahDirector
GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $14.75 $0.00
Disclosure

SEC source: 0001193125-26-085922 · ownership.xml · derivative · entry 1

Boyce Sarah · CIK 0001629383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-02-27

F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
February 27, 2026 Filed Mar 2, 2026 23:00 UTC GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $14.75 $0.00
Disclosure

SEC source: 0001193125-26-085921 · ownership.xml · derivative · entry 1

BOESS CARSTEN · CIK 0001277495 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-02-27

F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
February 27, 2026 Filed Mar 2, 2026 23:00 UTC GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $14.75 $0.00
Disclosure

SEC source: 0001193125-26-085920 · ownership.xml · derivative · entry 1

WILSON TROY EDWARD · CIK 0001589597 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-02-27

F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
February 27, 2026 Filed Mar 2, 2026 18:00 UTC GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $14.75 $0.00
Disclosure

SEC source: 0001193125-26-085919 · ownership.xml · derivative · entry 1

Flanagan W. Michael · CIK 0001841990 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-02-27

F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.